Who founded Qlaris Bio?

Qlaris Bio was founded by Thurein Htoo in 2019.

Who are Qlaris Bio's investors?

Qlaris Bio's investors include Canaan Partners, abrdn plc, Correlation Ventures, Mayo Clinic Ventures, New Leaf Venture Partners.

How much funding has Qlaris Bio raised?

Qlaris Bio has disclosed $41.8M raised across 4 rounds.

Where is Qlaris Bio headquartered?

Qlaris Bio is headquartered in Dedham, US.

Qlaris Bio

Dedham, US · Founded 2019 · Delaware corporation · 12 employees on LinkedIn · 5 known investors

Find your way into Qlaris Bio

Paths you didn't know you had: your email and LinkedIn already hold routes to the Qlaris Bio team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Qlaris Bio is a clinical-stage biotechnology company developing therapies for ophthalmology conditions. Its lead candidate, QLS-111, is a topical eye-drop treatment for glaucoma that lowers intraocular pressure by targeting episcleral venous pressure.

Biotech Medical Devices

Founders & leadership

Qlaris Bio was founded in 2019 by Thurein Htoo.

Thurein HtooChief Executive Officer & Co-Founder2019–2026

Fred Guerard President & Chief Executive OfficerFred Guerard is President and CEO of Qlaris Bio, a clinical-stage biotechnology company developing ophthalmology therapies. He brings over 20 years of pharmaceutical industry experience, including prior roles in public company leadership, and has worked across multiple therapeutic areas including ophthalmology, oncology, neurology, and cardiology.

Barbara WirostkoNamed on SEC filing

Board

Wende Hutton Board directorGeneral Partner at Canaan Partners

Ronald M. HuntBoard director

Andrew DanielsonBoard director

Adrienne GravesBoard director

Andrew DanielsenBoard directorMayo Clinic Chief Business Development Officer at Mayo Clinic Ventures

Investors · 5

Canaan Partnerslisted by Canaan PartnersStamford · $500K – $20Mvia Wende Hutton · board

How we know: Canaan Partners's portfolio page · a partner's Signal profile · board seat on SEC Form D · Not right? Tell us

abrdn plcreportedEdinburgh

How we know: funding news · glance.eyesoneyecare.com · Not right? Tell us

Correlation VenturesreportedSan Francisco · $100K – $4M

How we know: funding news · glance.eyesoneyecare.com · Not right? Tell us

Mayo Clinic VenturesreportedRochester

How we know: funding news · glance.eyesoneyecare.com · Not right? Tell us

New Leaf Venture PartnersreportedNew York

How we know: funding news · glance.eyesoneyecare.com · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$41.8M disclosed across 4 rounds · 2019–2026

▶$3.9MraisedJun 2026 · 8 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Barbara WirostkoExecutive Officer
Adrienne GravesDirector
Wende HuttonDirector
Robert WarnerDirector
Frederic GuerardExecutive Officer, Director
Ronald M. HuntDirector
Andrew DanielsonDirector

Offering amount: $3.9M
Amount sold: $3.9M
First sale: Jun 2026
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$5.6MraisedNov 2025 · 8 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Adrienne GravesDirector
Barbara WirostkoExecutive Officer
Wende HuttonDirector
Thurein HtooExecutive Officer, Director
Ronald M. HuntDirector
Andrew DanielsonDirector

Offering amount: $5.6M
Amount sold: $5.6M
First sale: Nov 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$24MraisedApr 2024 · 8 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Andrew DanielsonDirector
Ronald M. HuntDirector
Adrienne GravesDirector
Thurein HtooExecutive Officer, Director
Wende HuttonDirector
Barbara WirostkoExecutive Officer

Offering amount: $24M
Amount sold: $24M
First sale: Apr 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$8.2MraisedAug 2019 · 6 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Ron HuntDirector
Wende HuttonDirector
Barbara WirostkoExecutive Officer
Thurein HtooExecutive Officer, Director
Andrew DanielsenDirector

Offering amount: $27.3M
Amount sold: $8.2M
First sale: Aug 2019
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 7

QuralisQurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms. The company was founded by neuroscientists from Harvard to translate emerging discoveries about disease pathways into treatment breakthroughs for ALS patients.

TrisaluslifesciTriSalus develops a therapeutic platform combining its Pressure-Enabled Drug Delivery (PEDD) method with immune-activating therapies to overcome intratumoral pressure and immunosuppression that limit treatment of liver and pancreatic tumors. The platform is designed to be used alongside systemic immunotherapies such as checkpoint inhibitors for cancer patients.

Claris BioClaris Bio develops biologic therapies for sight-threatening eye diseases, with a current focus on bringing CSB-001, a novel treatment for patients with limbal stem cell deficiency, through clinical development and to market.

Aclaris TherapeuticsAclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases. The company's clinical and preclinical pipeline includes candidates in development for severe asthma, atopic dermatitis, and T-cell-mediated autoimmune conditions.

IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.

Arcus BiosciencesArcus Biosciences is a clinical-stage biopharmaceutical company that designs small molecule and monoclonal antibody combination therapies for people with cancer. Founded in 2015, it runs an in-house discovery and development organization spanning research through commercialization for oncology patients.

AlumisAlumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.

Companies working in the same space as Qlaris Bio.

In the news

Qlaris Bio Closes $24M Series B Financingfinsmes.com · Apr 2024

Frequently asked questions

What does Qlaris Bio do?: Qlaris Bio is a clinical-stage biotechnology company developing therapies for ophthalmology conditions. Its lead candidate, QLS-111, is a topical eye-drop treatment for glaucoma that lowers intraocular pressure by targeting episcleral venous pressure.
Who founded Qlaris Bio?: Qlaris Bio was founded by Thurein Htoo in 2019.
Who are Qlaris Bio's investors?: Qlaris Bio's investors include Canaan Partners, abrdn plc, Correlation Ventures, Mayo Clinic Ventures, New Leaf Venture Partners.
How much funding has Qlaris Bio raised?: Qlaris Bio has disclosed $41.8M raised across 4 rounds.
Where is Qlaris Bio headquartered?: Qlaris Bio is headquartered in Dedham, US.